Taysha Gene Therapies, Inc. (TSHA) Operating Margin
- Operating margin · 12 months: Value -2792.32%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -2792.32% | Operating income / revenue. Period ending 2026-06-30. $-153.16M ÷ $5.49M × 100 ≈ -2792.32% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -153.16M USD | Operating Income (Loss) |
| Revenue | 5.49M USD | |
| Cost of products and services | (m) | |
| Research and development | 123.14M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-153.16M | $5.49M | (m) | $123.14M | (m) | -2792.32% |
| 2026-03-31 | $-132.56M | $7.47M | (m) | $104.65M | (m) | -1774.37% |
| 2025-12-31 | $-110.50M | $9.77M | (m) | $86.40M | (m) | -1130.65% |
| 2025-09-30 | $-102.13M | $6.31M | (m) | $76.78M | (m) | -1618.54% |
| 2025-06-30 | $-94.00M | $8.10M | (m) | $65.98M | (m) | -1160.83% |
| 2025-03-31 | $-88.55M | $7.22M | (m) | $60.91M | (m) | -1225.78% |
| 2024-12-31 | $-91.46M | $8.33M | (m) | $66.00M | (m) | -1097.55% |
| 2024-09-30 | $-87.77M | $9.91M | (m) | $63.36M | (m) | -885.25% |
| 2024-06-30 | $-78.13M | $12.87M | (m) | $60.20M | (m) | -606.89% |
| 2024-03-31 | $-80.21M | $14.16M | (m) | $64.92M | (m) | -566.61% |
| 2023-12-31 | $-72.44M | $15.45M | (m) | $56.78M | (m) | -468.83% |
| 2023-09-30 | $-110.16M | (m) | (m) | $56.80M | (m) | (m) |
| 2023-06-30 | $-119.37M | (m) | (m) | $61.79M | (m) | (m) |
| 2023-03-31 | $-129.35M | (m) | (m) | $65.50M | (m) | (m) |
| 2022-12-31 | $-162.45M | $2.50M | (m) | $91.17M | (m) | -6492.69% |
| 2022-09-30 | $-157.05M | (m) | (m) | $115.23M | (m) | (m) |
| 2022-06-30 | $-182.66M | (m) | (m) | $138.36M | (m) | (m) |
| 2022-03-31 | $-190.44M | (m) | (m) | $145.89M | (m) | (m) |
| 2021-12-31 | $-173.27M | (m) | (m) | $131.94M | (m) | (m) |
| 2021-09-30 | $-141.91M | (m) | (m) | $106.28M | (m) | (m) |
| 2021-06-30 | $-106.27M | (m) | (m) | $77.81M | (m) | (m) |
| 2021-03-31 | $-69.51M | (m) | (m) | $50.23M | (m) | (m) |
| 2020-12-31 | $-43.00M | (m) | (m) | $31.89M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |